AIM-listed Advanced Oncotherapy (AVO) announced director and significant shareholdings this morning, following its latest fundraising in December and resulting share issues yesterday. But it seems that one of the directors has been – undisclosed – selling!
Shares in AIM-listed Advanced Oncotherapy are up by 30% today on the back of yet another technological update and a Flash Note from its paid-for research ramper-in-chief GPSL, the second in less than a week. Of course, yesterday the shares were down by around the same amount which all leaves me wondering when’s the placing?
This is undoubtedly good news for AIM-listed Advanced Oncotherapy (AVO) and the meagre 4% discount in quite a bonus. But I find it hard to get too excited.
AIM-listed Advanced Oncotherapy (AVO) released its FY17 numbers this morning. Looking through the numbers presented it is clear that the company was running on fumes last December. We are told that the company is in a stronger financial position since 31st December 2017 having secured £33.3m of financing post period end, but I wonder how much stronger?
AIM-listed Advanced Oncotherapy (AVO) announced this morning that Bracknor, the death spiral funder, still had convertible loan notes to swap for shares. This, despite the RNS of 19 July 2017 telling us that the Company does not intend to use the Bracknor facility in the future. As part of these arrangements the Company will issue 7 million warrants to Bracknor. These warrants are exercisable at 25p and may be exercised at any time over the next five years. Anyone would have thought that was the end of the matter. Apparently not.
AIM-listed Advanced Oncotherapy finally got around to updating the market over its Blackfinch loan which matured on 24 March and was secured on its Harley Street premises. But it seems that the company can’t tell the truth!
As we know from AIM-listed UK Oil and Gas (UKOG), the best thing to do when faced with an awkward question is to move the goal posts. And so this morning we see AIM-listed Advanced Oncotherapy (AVO), rather than ‘fess up over its overdue loan from Blackfinch which is secured on its Harley Street premises, telling us that it has signed a lease with the UK Government’s Science and Technology Facilities Council to establish a UK testing site for its LIGHT (proton therapy technology) system. I wonder what Advanced is going to pay with!
AIM-listed Advanced Oncotherapy (AVO) has still not updated the market over its Blackfinch loan which was due to expire at the end of March, a loan which was secured on the company’s Harley Street premises. I also have doubts (still not answered) over the cash from China. But on re-reading through the note from Goetzpartners (which sent Advanced stock much higher on publication) I wonder if I have inadvertently been taking some of Tom Winnifrith’s mushrooms.
So after my piece HERE wondering why AIM-listed Advanced Oncotherapy (AVO) was up 20-odd per cent it turns out that a research note was put out on the RNS system. The research note was from an outfit called Goetzpartners Securities Limited, which claims to be a leading pan-European investment bank and research firm. Right…. So who paid for this research, and is it worth the paper it is written on?
As yet AIM-listed Advanced Oncotherapy (AVO) is yet to answer my questions about the Blackfinch loan which is secured on its Harley Street premises and which was due to expire back on 24 March. It has also ignored my questions about the Chinese funding from Yantai Cipu as to whether any funds have actually arrived with Advanced. These two questions seem to me to be pertinent to Advanced's very survival, but all we have had is a wall of silence. You would have thought the market would get jittery, but out of the blue today its shares are up a whopping 22% (last seen).
Yet another day passes and still AIM-listed Advanced Oncotherapy (AVO) has not answered my questions, and so I ask again – now for the eleventh time. They are serious questions and with the wrong answers I would struggle to see how the company is solvent. But Advanced continues to ignore the questions. So here we go again….
And so yet another day passes and still AIM-listed Advanced Oncotherapy (AVO) has not answered my questions, and so I ask again – now for the tenth time as we head into double figures.
Yet another day passes and still AIM-listed Advanced Oncotherapy (AVO) has not answered my questions, and so I ask again – now for the ninth time…..here we go again:
Yet another day passes and still AIM-listed Advanced Oncotherapy (AVO) has not answered my questions, and so I ask again – now for the seventh time. At this rate Jeremy Paxman’s score of 12 (against Michael Howard) is in danger. I have had it pointed out to me that Paxo asked the questions face to face, and in that regard I can’t match him. But at least (now) Lord Howard had to reply – even if he evaded the actual question. Anyway, here we go again:
Yet another day passes and still AIM-listed Advanced Oncotherapy (AVO) has not answered my questions, and so I ask again – now for the seventh time. At this rate Jeremy Paxman’s score of 12 (against Michael Howard) is in danger.
Another day passes and still AIM-listed Advanced Oncotherapy (AVO) has not answered my questions, and so I ask again. What is happening with the Blackfinch loan which had a 12 month term starting on 24 March last year, a loan which was secured on the company’s Harley Street premises? And has the company actually received any cash at all from its white knight saviour Yantai Cipu in China?
This really is getting a bore. For the fifth time, I ask what is happening with the Blackfinch loan which had a 12 month term starting on 24 March last year, a loan which was secured on AIM-listed Advanced Oncotherapy’s (AVO) Harley Street premises. And for a fifth time I am asking if the company has actually received any cash at all from its white knight saviour Yantai Cipu in China. But first, there is a question raised by Drunken Sailor.
My thanks to two eagle-eyed ShareProphets readers who have posted in the comments sections of my pieces asking about AIM-listed Advanced Oncotherapy (AVO) and its funding from Yantai Cipu in China, and the now expired, secured (on Advanced’s Harley Street premises), Blackfinch loan. We’ve still not heard a thing about either which is rapidly drawing me to a conclusion as to the answers. Not to worry: I’ll ask (for the fourth time) again tomorrow. But, with big hat-tips to Drunken Sailor and Daniel Victor, it seems that Advanced isn’t even getting over the line at Harley Street before two other proton therapy centres (one of which is up and running already) come on stream. It seems that first mover advantage has already been lost.
I have asked the same questions of AIM-listed Advanced Oncotherapy (AVO) twice before but there has been nothing forthcoming from Advanced Towers. Here we go again, on the day that marks three weeks from the end of Advanced’s loan from Blackfinch, a loan which is secured on its Harley Street premises and a loan which has not yet been announced to have been paid back. Advanced may be coy about answering, but it seems the market has been voting with its feet.
It is now a week into April, yet AIM-listed Advanced Oncotherapy (AVO) has not updated on its loan from Blackfinch which was due to be repaid – I thought – at the end of March. In fact, it appears that the loan matured on 24 March. Worse, the loan was secured on Advanced’s Harley Street site and, it seems, the equipment earmarked to be installed there. One wonders what would be left if Advanced lost that. Surely a statement is a fortnight overdue as to what is going on?
Yesterday AIM-listed Advanced Oncotherapy (AVO) announced that the Long Stop Date for the completion of a Distribution Agreement with Yantai Cipu, already extended to 31 March, had been exceeded but discussions were continuing. This deal also involves the payment of £16.5 million to Advanced and it seems the cash is yet to arrive – indeed I wonder if the £13.5 million subscription cash arrived. That in turn leaves me wondering, yet again, what the cash position at Advanced is – and what about the £5.5 million Blackfinch loan which should have been repaid at the end of March (and is secured)? Are the wheels coming off the white knight rescue? Surely a full statement is needed?
With a litany of Red Flags behind it, you might wonder that AIM-listed Advanced Oncotherapy (AVO) has managed to raise any money at all, but this morning’s news is – it seems – good news. Cash coming in (and large quantities of it) should pay down the payables nicely and give the company some breathing space – although we are told that the cash is still in China awaiting approval to be shipped out by the authorities. Followers of the ShareProphets AIM-China Filthy Forty might consider that as an indication that the completion of the deal is rather open to question.
AIM-listed Advanced Oncotherapy (AVO) has released its interims results on deadline day. The highlights (if that is the right word) come from the cashflow statement, where cashburn appears to be almost £2 million a month. And then there is the company’s statement of working capital which, although technically correct, is a grossly misleading figure.
Joining in with Cynical Bear’s run of interims previews, I thought I’d take a look at our old favourite, AIM-listed Advanced Oncotherapy (AVO). The history here has been nothing short of a disaster in the last 12 months or so, and appears to be now culminating in a potential cash-crisis.
Shares in AIM-listed Advanced Oncotherapy (AVO) are still languishing well below the par price of 25p and the company must surely by now be running pretty low on cash. But a look at the FY16 accounts throws up some interesting questions over remuneration.
After a stack of RNSs earlier this year, it has all gone quiet at AIM-listed Advanced Oncotherapy (AVO) since the announcement of the termination of the Bracknor death-spiral. How’s the cash position?
AIM-listed Advanced Oncotherapy has announced a director buy of 100,000 shares (about £17,750 worth). Dr Enrico Vanni, a NED, has gone into the market and hoovered up a few more shares to add to the series of shares acquired earlier this year as the company tried (and failed) to defend the 25p (par) share mark in the face of the Bracknor death spiral sales. Now he’s back.
AIM-listed Advanced Oncotherapy (AVO) has announced that the final Coupled Cavity Linac (CCL) module (part of the LIGHT system) is ready for shipment to the company’s Geneva Testing facility. All very good news, no doubt, but what is the cash position of the company?
Tom and I covered this the other day, but I wonder whether we’ve missed a trick with regard to AIM-listed Advanced Oncotherapy (AVO) and its dealings with death spiral sharks Bracknor. Immediately prior to last week’s funding news my back-of-an-envelope calculation was that Bracknor still held £1.95 million of loan notes and a further £0.7 million from fees. Given that Bracknor held little (if any) shares, why has it not beaten a hasty track to get the loans converted so that it can sell into the resulting strength?
AGM day for AIM-listed Advanced Oncotherapy (AVO) and it has pulled something out of the hat. The shares have shot higher, death spiral outfit Bracknor is history and Advanced doesn’t look like going bust now for at least 4 months. But is the deal as good as believed? Er..no.
Cynical Bear wonders whether there might be a read across to AIM-listed Advanced Oncotherapy (AVO) from today’s news from suspended-pending-clarification Kin Group (KIN) in the wake of its announcement that its funding partner had walked because the share price had fallen so far. Certainly, given the cash-back situation for any loan note conversion by Bracknor into Advanced shares there looks to be a point at which the situation breaks down..
Shares in Advanced Oncotherapy (AVO ) are again tumbling on this fine summer's day. Oh what joy it is to be alive. 350p at peak ramp less than two years ago, they are now just 10.75p to sell. Ouch, I just love the smell of burning share certificates belonging to Bulletin Board Morons in the morning. So what crisis looms? Take your pick.
The stench of desperation at AIM POS Advanced Oncotherapy (AVO) is overpowering.It knows that insolvency looms, that the money is running out fast ( within weeks?) and that a blizzard of share sales from death spiral provider Bracknor will obliterate the share price in the last few days. The board know it. The advisers must know it. But they cannot bring themselves to admit it. The pretence goes on for a while yet. And thus today we have an RNS.
In a sense this is not that relevant as Advanced Oncotherapy (AVO) is within a couple of months of running out of cash and going tits up but on a point of principle I have written to the my very good friends at the Financial Reporting Council as there are aspects of Advanced's 2016 annual report and accounts which stink more than a pile of rotting kippers left out at a sewage farm in the scorching midday heat. The letter follows:
AIM-listed Advanced Oncotherapy (AVO) has released its full Annual Report. Having looked yesterday at a few things I thought it would be worth a second look – especially in the light of a clean audit report from RPG Crouch Chapman. Mea culpa to myself and Tom who expected something different, but hang on a minute…
AIM-listed Advanced Oncotherapy(AVO) has released its final results RNS for 2016 with four days to go before deadline day Bully for Advanced. But there are no notes to the accounts and why is there no no auditor’s statement – the very things that we were looking for. What is the company hiding? We are told that the report WILL be made availlable on the website but hang on...this is crucial!
Advanced Oncotherapy (AVO) shares have fallen from a ramptastic peak of 350p to just 13.5p to sell as at last Friday. But sell you should as I explained again today HERE. The question is what will the shares be trading at ( mid) as at next Friday which is a critical deadline. What do you think? Let's gloat on the professional graves of scumbag crony capitalist Dr Michael Sinclair, arch share ramper Alan Green and PR low life Paul "Queenie" McManus. With a deadline of 7 AM Monday 26th vote now in the poll below.
Yesterday I revealed to you the 18 shares I own and thanks for all the comments. For the avoidance of doubt that portfolio started at zero four and a bit years ago and we have more than trebled our money to date. It happens. But I lied to you, the portfolio is incomplete. I own two other shares.
AIM-listed Advanced Oncotherapy (AVO) has announced the latest death spiral on steroids conversion by Bracknor: £400,000 into 1.6 million shares. But with the shares sitting a country mile below the 25p nominal price they have to pay £190,000 back. That works out as 11.875p per share and thus means that Bracknor gets its new confetti at just (effectively) 13.125p. Not bad, bearing in mind that the lowest daily VWAP came in at 15.79p.
I have never seen a loan like this. It is sheer desperation from a company that faces imminent insolvency. Make no mistake, Advanced Oncotherapy (AVO) is on the way out and corporate death will occur very soon indeed.
Shares in doomed Advanced Oncotherapy (AVO) are now 15.25p to sell, compared to a 25p nominal price. That means that as death spiral provider Bracknor desperately tried to convert c£3 million on loan notes into shares to flog to eliminate its exposure under the spoof arrangement with Advanced it will demand fees of 40p for every £1 of loan note converted. As it scrambles to convert notes and flog shares before the fat lady waddles onto stage from the wings (where she is already warming up), the share price will continue to tank making things even worse. So what to do?
With its hand forced by my article HERE, Advanced Oncotherapy (AVO) has clarified, i.e. changed, the terms of its death spiral deal with loan sharks Bracknor. It states "This reaffirms Bracknor's prior and on-going support for the Company and its shareholders." Dr Michael Sinclair you are talking bollocks. It has changed a death spiral to a death spiral on steroids.
Wakey wakey Michael Sinclair and the other tossers who run Advanced Oncotherapy (AVO). Time to get out of the luxury gym ( membership fees paid by grateful shareholders) - you need to be issuing a statement don't you? Bracknor? 10 days? Capital Reorganisation? Ring any bells? Come on, call your useless PR man Paul Queenie McManus and tell him to stop promoting the Eden fraud and get a release ready for you.
AIM-listed Advanced Oncotherapy (AVO) has this morning announced another conversion of death-spiral loan notes by Bracknor. That is not news – there have been plenty already and there are many more to come. But for the third time in succession we seem to have different terms being applied. Surely it is time for the company to tell the market what is going on?
I can’t help but notice that in the wake of a couple of Bracknor death-spiral loan note conversions, shares in AIM-listed Advanced Oncotherapy have rather slipped again. Indeed, having scraped onto the 27.5p watermark on Monday last week (and thus avoided an EGM to drop the nominal price of the shares) as the result of spoof boardroom buying, it has been one-way traffic ever since, down to 22.75p last seen.
Well, well. How do you issue shares at a discount to par? Simple: pay a whopping fee to the subscriber. AIM-listed Advanced Oncotherapy (AVO) has announced another loan note conversion under its death-spiral funding package with Bracknor and a new fee seems to have appeared which might just derail discussions between the company and its auditor as they work on the going concern statement for the forthcoming FY16 results due out by the end of next month. Oh dear, oh dear.
Well this is most bizarre! Lobster-potted Bracknor has converted another lump of its death-spiral loan notes. That, of course, is not a great surprise until you study the detail of yesterday morning’s announcement from AIM-listed Advanced Oncotherapy (AVO), where we discover that the conversion shares have been issued not at the lowest daily volume-weighted average price of the past 15 days (21.35p) as per previously announced conversion terms, but at 25p (par price of the shares). Why has Bracknor elected to pay a 17% premium?
Well it looks as though D-day is today after all for the triggering of an EGM to drop the nominal (par) price of AIM-listed Advanced Oncotherapy (AVO) stock so as to allow Bracknor to resume its convert-and-dump operations. With the shares edging a little higher this morning, one is tempted to wonder whether some heavy boardroom buying might be enough to lift the shares back over the 27.5p mark just in the nick of time. But there is a fair way to go, with the stock still 2.25p short of salvation.
Under its Bracknor death-spiral funding package, AIM-listed Advanced Oncotherapy (AVO) has to call an EGM proposing resolutions to drop the current nominal, or “par”, 25p price of its shares by at least half in the event of 10 consecutive closes below 110% of nominal (ie below 27.5p). But the company has never defined the closing price used: is it mid-price, bid-price, offer-price at close, or perhaps some more convoluted closing daily VWAP (volume weighted average price) calculation? But one thing is for sure, the match is right next to the blue touch-paper. Is it today or Monday, fellas?
Advanced Oncotherapy (AVO) has announced that NED and highly respected senior clinical oncologist at Great Ormond St and Barts Dr Nick Plowman “will” invest £250,000 in the company – at 30p a share, a 36% premium to last week’s close. Why am I not convinced that this morning’s announcement is anything other than the most desperate of spoofs in a long line of spoofs here?
ShareProphets readers don't expect an immediate implosion on Advanced Oncotherapy (AVO). They're leaving it to Father Christmas to do the job. We asked you when the shares would hit 0p - you said!
AIM-listed Advanced Oncotherapy (AVO) has a calendar year-end and as such its six-month deadline to publish accounts falls on 30 June – the end of next month. That means getting an audit done which will involve, amongst other things, agreeing the Going Concern statement. Yesterday’s share price plunge might have more than a small bearing on how conversations go in that regard.
Shares in AIM dog Advanced Oncotherapy (AVO) closed Friday at just 21p. That is below the 25p nominal meaning that death spiral provider Bracknor cannot convert any more loan notes without taking a huge loss and, if that continues, it means the company will go tits up in the summer. Or the former Malcolm Stacey darling will need to approve a capital reconstruction to set a new nominal (2.5p?) which will see the shares plunge, so meaning Bracknor physically can't convert loan notes so Advanced will go tits up this summer. So when will its shares hit 0p or be suspended from AIM? Vote now in our reader poll - deadline midnight tonight.
You can’t say you have not been warned. This morning shares in AIM-listed Advanced Oncotherapy (AVO) have fallen firmly below the nominal 25p price of the confetti. Companies are not allowed to issue shares below their nominal price and that, in turn, means that for the time being Bracknor is lobster-potted with something like £2.5 million of convertible (death-spiral) loans which it cannot convert. My heart bleeds….
Oh dear. Oh dearie me. AIM-listed Advanced Oncotherapy (AVO) has released a TR-1 from institutional investor Aviva showing that it has been dumping shares and went below the disclosable threshold to 2.44% last Friday in terms of its directly held interests. It had a further 0.66% interest via loaned out shares. Meanwhile Advanced Onco shares today fell below the 25p nominal price of its confetti, leaving death-spiral funder Bracknor in a bit of a pickle just five days after ponying up tranche 2 of convertible loans which it can’t convert for less than 25p. Ouch.
The final two pages of listings of AIM-listed Advanced Oncotherapy (AVO) Exec Chairman, Michael Jeffrey Sinclair’s company officer posts on the OpenCorporates.com website add another 27 entities to our previous tally (after ignoring a further 6 double entries) of 113 appointments to bring the total up to 140 jobs in an illustrious career. And so we have the final scores-on-the-doors – as well as an interesting observation.
AIM-listed Advanced Oncotherapy (AVO) has announced this morning the drawdown of the second tranche of £1.3 million (nominal - £1.235 million after the 5% discount) on its convertible loan note (aka death spiral) package with Bracknor. Good news – the lights will stay on for a few weeks extra. But the second half of the statement is a bit of a puzzle, raising more questions than it seemingly tries to answer.
Well that explains it then! Yesterday I noted my amazement that AIM-listed Advanced Oncotherapy (AVO) had issued yet another ramparoonie director share purchase RNS on Tuesday and that the shares had raced back above not only the all-important 27.5p mark, but above 30p. Now we know why: Executive Chairman Dr Michael Sinclair was in the market filling his boots with 200,000 shares at an average price of 30.44p. Shame he didn’t pile in when the shares were hovering around the 26p mark so as to save himself a few quid.
We are nearly there. Hurrah! The OpenCorporates.com website lists 153 company appointments for a Michael Jeffrey Sinclair spanning some six pages. Today we move into page four to see how the rate of dissolutions looks.
At no-one-is-watching o’clock last night (5.48 pm) AIM-listed Advanced Oncotherapy (AVO) slipped out an announcement that it had drawn the £2m second tranche of cash available under its one-year loan deal with Blackfinch. With my maths suggesting that the company was close to running on fumes that extra £2m to keep the show on the road pro tem will come in handy.
Phew! 153 company directorships to plough through from the career of AIM-listed Advanced Oncotherapy’s Executive Chairman. He sure has been a busy chap. Actually the number is dropping slightly as a few more double entries come up on the OpenCorporates.com website – just as well. Having looked through the first 30 entries on Sunday (29 after sifting out double entries) and the same again yesterday, we come to the next 30 from our search of the career of Dr Michael Jeffrey Sinclair.
AIM-listed Advanced Oncotherapy (AVO) – teetering on the brink of having to call an EGM to reduce its nominal share capital under the terms of its death-spiral funding package with Bracknor – has announced yet another director share purchase, the fourth just this month (if we ignore the botched 7am RNS of 4 April). As ever, this is just a spoof in order to encourage more buying in the market so as to allow Bracknor to offload more of its death-spiral conversion shares as Advanced hopes and prays for the next £1.235 million tranche of funding before the coffers run dry.
Yesterday we wandered through the first page of search results on the OpenCorporates.com website to look at the record of AIM-listed Advanced Oncotherapy (AVO) Executive Chairman Dr Michael Jeffrey Sinclair. There are rather a lot – here comes page 2.
AIM-listed Advanced Oncotherapy (AVO) Exec Chairman Dr Michael Jeffrey Sinclair has, according to the OpenCorporates.com website, served as an officer of 155 companies over his illustrious career. With Advanced Onco facing a few issues of cash as it tries to get its Harley Street facility installed and running, it is perhaps worth a gander through this record. Here are the first 29 listed on the OpenCorporates.com website (actually it is 30, but one appears to be a double entry so has been removed).
As shares in AIM-listed Advanced Oncotherapy (AVO) again sit below that all-important 27.5p mark which, if continued for 10 trading days, will trigger a EGM to reduce the nominal value of the company’s shares, a quick trip to the Companies House website reveals the debenture paperwork (HERE) related to the company’s recently announced loan deal (with spoof 100p conversion terms) with Blackfinch as announced on 27 March (HERE). Most of it is legalese, but on page 36 we get some cracking tit-bits. Such as the planned expenditure on the Harley Street premises (some £19.14 million) as against potential resale values of between £9.44 million and £10.71 million – and that is just for the kit and fitting, not for the value of the property itself. As security (including the property) for a £3 million loan (with an option for a further £2 million) it is quite something!
This morning AIM-listed Advanced Oncotherapy (AVO) announced another conversion by Bracknor. Having previously converted three lumps of £100,000 of death spiral loans, Bracknor has gone for £200,000 worth this time – but at the lowest price yet, just 26.74p. That leaves things looking decidedly sticky for the company, which got authority to issue Bracknor with enough loan conversion shares based on the assumption of an average loan conversion price of 44p and the associated warrants at 57p.
Under its death spiral funding package with Bracknor, AIM-listed Advanced Oncotherapy (AVO) has to call an EGM to seek shareholder approval to reduce the nominal price of its shares (currently 25p) by at least half if the closing share price is below 110% of nominal (ie 27.5p) for ten consecutive trading days. And that brings us to the latest spoof director share purchase announced this morning (which hasn’t worked: the shares are down 4% last seen this morning).
AIM-listed Advanced Oncotherapy (AVO) has this morning announced another loan conversion by its white knight death spiral funding provider Bracknor. The lack of liquidity of late makes it hard to imagine that Bracknor is having an easy time offloading. Meanwhile the shares have again slipped and now sit below the threshold at which an EGM to reduce the nominal price of the shares is triggered. Oh dear….
AIM-listed Advanced Oncotherapy (AVO) has announced a second conversion of death-spiral loan by Bracknor. As per the first conversion, it is £100,000 (nominal) but this time the conversion price was just 27.89p. Given that the recent EGM gave approval for the company to convert the full package at an average 44p per share that might mean a bit of a headache.
Following the botched Director Dealings RNS of Tuesday, this afternoon AIM-listed Advanced Oncotherapy has ‘fessed up to another foul-up. This time it refers to an RNS released way back on November 7th last year when the company announced that it had issued 266,668 new shares from the exercise of options at 87.5p per share. Except that it hadn’t.
It seems that AIM-listed Advanced Oncotherapy (AVO) is so desperate to get out any good news it can that it rushed out an RNS yesterday morning to notify the market of director buying and got the numbers wrong. Oops. Great work in checking and verifying there by Nomad Stockdale Securities.
Sadly I decided to rush up to Warwick to see my father on Friday so I missed out on attending the GM of Advanced Oncotherapy (AVO). The heading for bankruptcy company put out a statement which, needless to say, is a 100% rum and coke. Advanced was covered in the bears session at UK Investor Show on Saturday and we will have a video up of that in due course. Now back to that GM where the statement comes with our translation in bold
It has arrived! My £52 costs and 32p investment in one share in AIM dog Advanced Oncotherapy (AVO) is not money wasted.
Ho ho ho. Even as it faces insolvency those wags at Advanced Oncotherapy (AVO) do so with a sense of humour as they try to spoof us all with news of an even more desperate financing which will keep the lights on until late June. Dr Michael Sinclair you should go on the stage. You really are a hoot.
It is just eight days to the GM of Advanced Oncotherapy (AVO) where shareholders are being asked to approve the issue of gazillions of new shares for the Bracknor death spiral. Since the alternative is going bust within weeks if not days then the result is a gimme although I intend attending - as the owner of 1 share - to ask some searching questions. But the collapse in the share price - the stock is now 31.5p mid, 30p bid tells you there are even bigger issues and that Advanced is, quite possibly toast whatever.
Death spiral provider Bracknor does not buy shares in companies. It loans the desperate, cash at pound of flesh rates which it then converts into shares at discounted rates and flogs to mug punters. That is the classic death spiral model. But to get such a death spiral away it needs a perception of market liquidity and also to avoid a complete short term collapse of the share price. And that brings us to Advanced Oncotherapy (AVO).
Advanced Oncotherapy (AVO) is, as you know, utterly desperate to create buying interest in its shares so that death spiral shysters Bracknor can dump £13.7 million of equity onto the market over the next year. That is not going well and so Advanced today boasts that it has paid investment analyst prostitutes for hire, Hardman, to publish a glossy note. This report is so unbelievably unbalanced that I can only assume that Hardman outsourced the work to the Bulletin Board Morons on the LSE Asylum. Folks can see through this shite and the shares are down by a penny at just 40p bid which is very bad news for Advanced as explained HERE.
I have already covered the admissions (HERE) and lies (HERE) flagged up in today's notice of a GM published by Advanced Oncotherapy (AVO). The great news is that the GM is on March 31 in London, a day when I shall be in the Capital. As the proud owner of 1 share bought earlier this week I shall be there for a bunfight. Just 32p for so much fun - bargain! Get your beer & popcorn ready. Why not come along to join me in giving the board hell over all the lies and other matters? There is free beer on me at Wedge Issue afterwards. But there is a far more serious problem for the shysters.
Heading to zero, serial liar Advanced Oncotherapy (AVO) has today called a GM to approve the issue of a blizzard of shares to obliterate its share price via death spiral. More on that later but the documentation throws up another issue other than the lies refered to earlier HERE, why will Advanced NOT come clean on short selling by death spiral provider Bracknor.
Advanced Oncotherapy (AVO) has today called its GM to approve the issuance of more shares to feed the Bracknor Death Spiral - more on that later for the document is, like the company, a joke. But first lets go to a big fat monstrous lie it told last year to help get that bailout placing away in September.
I am beginning to think that the 32p I invested in buying one share in Advanced Oncotherapy (AVO) may be dead money sooner than I think. The silence on certain matters relating to the £11 million it owes Metric is deafening and leads me to believe that on March 31 this company could be insolvent. Or is it already insolvent? The first question is whether Advanced has breached covenants on the loan already and so is in technical default, i.e. insolvent. If that is the case investors should be told at once should they not. Perhaps hapless Nomad Stockdale might force a clarification of this matter?
Shares in Advanced Oncotherapy (AVO) are sliding again today. Last time I looked they were 32p bid and they are heading rapidly towards the 25p mark at which point Bracknor will not be able to forward sell/convert loan notes as explained HERE without GM sanction. Thus the loan shark death spiral provider - which is pro tem exposed to the tune of well over £1 million will be flogging shares as fast as it can. Meanwhile Advanced just won't answer my 16 questions HERE. But there is something else going on which you can see if you check out the Bulletin Boards and it is quite remarkable and shows this company is toast.
Cynical Bear says that I am just being far too kind to Advanced Oncotherapy (AVO) with my 15 questions earlier today. Oddly I have yet to get an answer and nor will I as the company contemplates insolvency and other matters. But back to Mr Bear who says I should have asked a 16th question concerning another possible case of lying.
For years Advanced Oncotherapy (AVO) has ramped its shares to get away placing after placing with ramptastic investor presentations. But that was before I started asking all those horrible questions for which there was no answer. and Winnileaks started obtaining toxic leaked emails. Last night the company had a presentation in London. It has another in Zurich this morning. Warning Swiss folk and tax dodgers quotes about the London chinwag include "everyone left unhappy" and from a long term bull "I am just throwing in the towel." The shares have crashed by 23% to 36p bid so far today. The target for me remains 0p. But for those folks going to the Zurich meeting here here are 15 questions Advanced can't or won't answer:
When AIM uber dog Advanced Oncotherapy (AVO) announced that instead of going for non dilutive funding ( as no-one would provide it) it was being forced to resort to a dreadful £13 million death spiral from loan sharks Bracknor, its shares were 65p. When the death spiral started the shares were 58p. Now it just £100,000 of the death spiral loan notes on the first £1.3 million tranche converted, the shares are just 43p to sell. Bracknor now has three reasons to panic.
Advanced Oncotherapy (AVO) the company with sod all cash, that is a cash guzzler, with no sales and which has persistently misled both investors and customers has moved up a gear with its death spiral funding and the shares have fallen again to just 49p to sell. Boy how sleazey former director, the Blair crony, Lord Evans of Watford must be glad that he dumped all his shares at 120p just ahead of the last big placing and during a closed period. And there has been no sanction at all. Bully for him. Now back to the death spiral.
Hello Share Tumblers. Uncle Tom has had Advanced Oncotherapy (AVO) under his gimlet eye for some time now. A few months ago, after a particularly worrying piece, I sold all this family’s holding for a stonking loss.
If you had raised £10 million for the AIM dog Advanced Oncotherapy (AVO) less than 5 months ago at 100p then your stance on the stock - at 54p-58p- would be some sort of buy. Oh no. broker Beaufort who did indeed raise that cash has today downgraded its stance to, what may be termed a corporate "hold" (i.e. sell) and makes it clear that the shares will fall allowing lower entry points. I should cocoa. Beaufort today opines after the Bracknor death spiral announcement of Friday - the underlines are mine:
Having promised "non dilutive funding" ad nauseam, on Wednesday AIM listed POS Advanced Oncotherapy (AVO) announced a £13 million death spiral funding with are shylocks Bracknor. On Friday it drew down tranche one and promptly served up another dose of smoke and mirrors for punters. The death spiral dance is now underway. Advanced announced that:
Yesterday I pointed out how the £13 million death spiral Advanced Oncotherapy (AVO) had signed with loan sharks Bracknor would see its share price collapse. It should but there is worse news in store - that of insolvency looming in just five weeks time. Insolvency you say? What are you talking about? Let me explain.
I have noted before that some death spirals are in fact a decent way for companies to raise cash, cheaper and less share price destructive than a bucket shop placing. But the Bracknor deal announced today by Advanced Oncotherapy (AVO), which had promised non dilutive funding but clearly does not mean a word it says, as I explained here earlier, is a total rotter. It will crater the share price as Bracknor makes a killing. Let me explain why.
Serial misleader and worthless bag of AIM listed shite Advanced Oncotherapy (AVO) today announced that it has secured death spiral financing for £13-26 million from the lowest of the low DS funders, Bracknor. That is bad enough and will see the shares forward sold to buggery, as I will outline in a separate piece. What is worse is that it exposes Advanced for again misleading investors.
Last week's Bulletin Board Moron contest produced a number of splendid entries demonstrating that the "World's Most Successful Growth Market" attracts "the World's stupidest investors". You can see the full range here but the winner is an Advanced Oncotherapy (AVO) owning moron.
Advanced Oncotherapy (AVO) has finally fessed up to the truth of its bust up with Sinophi and is paying the Chinese $250,000 to settle - even last week house broker Beaufort was, with an Advanced steer, suggesting the Chinese would be paying Oncotherapy several million quid. Lets remind ourselves of a timetable of lies, deception and non disclosure.
This is becoming something of a ritual. Advanced Oncotherapy (AVO) is tardy in releasing very bad news but eventually fesses up. But it misleads investors. Its (now very clearly former) partner Sinophi then, effectively, accuses it of lying. Oh dear, for the second time Sinophi has stated that (almost insolvent) Advanced is telling porkies.
I had a couple of contacts attending Thursday's attempted rampfest by floundering Advanced Oncotherapy (AVO) hosted (for a fee) by the sleazy IR promoters at Proactive Investors. I am grateful to one financial analyst - who is short of the stock - for his notes.
On December 2 2016 I suggested here that Advanced Oncotherapy NED Tim Lebus had had enough and was walking. The lying snot-gobblers round at Advanced declined to comment. Guess what? He has walked with immediate effect today. It gets better, if you are a bear.
Yesterday I goaded AIM weasels Advanced Oncotherapy (AVO) to come clean on the status of its relationship with Chinese distributor Sinophi, HERE. It seems the world moves quickly because Advanced has today announced that Sinophi has, as of yesterday, "terminated" its orders and at a stroke the order book goes from $150 million to nil. But this smells all wrong and at the same time means that Advanced may well go bust within five weeks. Let me explain.
Advanced Oncotherapy (AVO) said in September that it would secure additional non dilutive funding by the year end. Today it is clarified where it stands but has neglected to point out how perilous its financial position is. Net current assets will be negative within five weeks which begs a real question regarding whether this company is solvent
AIM (very) bad boy Advanced Oncotherapy (AVO) did its best to ramp its shares following the shock loss of its entire order book back in November. Or was it October? Glitzy promo videos and spoofing share purchases by NEDs phased out to have maximum effect on fooling the gullible managed to get the shares back to c90p. But now folks are looking behind the smokescreen of bullshit and the shares are tumbling again, to 73.5p. Since this company has committed securities fraud my target remains 0p. The questions are mounting fast.
As joint house broker to the exponent of Securities fraud that is Advanced Oncotherapy (AVO), Beaufort has to sound bullish and has thus reiterated its speculative buy stance today. But read the note carefully. Beaufort is frit. I have highlighted key phrases that have not appeared before for you. Key phrases which show goalposts being moved and a broker that is sick of being made to look foolish.
It is now 11 days since I published details of leaked emails which showed that AIM scumbag Advanced Oncotherapy had withheld awful trading news from investors as the company launched an open offer. That is clearly securities fraud. Almost as bad, the emails showed that the timelines the company had held out to both customers in China and investors in London for product delivery were just fantasy. And that is why customers walked. Heads should have rolled. Hapless Nomad Stockdale should have forced a statement. And having told its house broker (Beaufort) that a much needed refinancing would happen by the year end, we need an update on that too. Instead...
Time is running out for Advanced Oncotherapy (AVO) as it scrabbles for additional finance but this time it really needs to start telling the truth to potential backers. In fact before I reveal more leaked emails I invite it to correct some previous lies told now.
Hello Share Shiners. The decaying share value of Advanced Oncotherapy (AVO) after and during inquiries by Uncle Tom will have left a fair few of us nursing losses. My own shortfall after selling my shares is not to be sniffed at.
Yesterday I published extracts from leaked emails that show that Advanced Oncotherapy (AVO ) kept very bad news regarding China contracts from investors as it launched and conducted an open offer. That is monumentally serious. In the US folks would already be doing a perp walk fort that but even our useless regulators will do something here. In normal circumstances the company would issue a response via RNS but here we are a day and a half later and even though the shares slumped yesterday and are sliding again today we hear only a deafening silence.
AIM promote Advanced Oncotherapy (AVO) and Sinophi have already publicly disagreed as to whether the $120 million order by the Chinese has been "terminated" or not and and on when it was "terminated". Advanced announced the bad news on November 24 suggesting no termination, Sinophi used the T word and said it told Advanced in "early November". A source out East has ensured that I have now obtained access to confidential emails from Sinophi to Advanced which show that Advanced was aware of problems far earlier and at a time when it was soliciting funds from investors. It did not tell those investors. Heads must roll.
Tim Lebus is a non executive director at Advanced Oncotherapy (AVO). Well sort of.
In the face of relentless pressure from this website, embattled Advanced Oncotherapy (AVO) yesterday put out a statement attempting to draw a line in the sand over its falling out with Sinophi, whom it had claimed was set to buy $120 million of machines from it. It has failed. the statement begs even more questions and the shares remain utterly uninvestable.
Advanced Oncotherapy's (AVO) much ramped JV with China based Sinophi is falling apart in the most embarrassing of ways. Advanced announced its first deal with Sinophi on March 25 2015, a statement made by Sinophi should have the FCA and AIM regulation crawling all over this one.
Yesterday shares in Advanced Oncotherapy (AVO) plunged after it fessed up that a critical deal worth up to $120 million with a Chinese entity had encountered problems. Those who backed a big fundraise just weeks ago are already 26% down. But the incident begs massive questions about the timeline of disclosure and RNS statements that appear to be utterly untrue. I have written to the FCA & AIM Regulation, as this appears to be market abuse, outlining my very specific concerns and demanding an urgent enquiry and, if appropriate, that sanction be taken against those responsible. The letter is below:
Hello Share Mongers. About two years ago I suggested you take a look at Advanced Oncotherapy (AVO). I was glad I did as I seem to recall that the shares rose from about 3p at the time to around 18p.
How many commercial orders does Advanced Oncotherapy (AVO) have for its Proton beam machines? I put it to you that the answer is zero but that it has always been zero. This company appears to have over-egged the pudding on a serial basis, allowing it to raise vast sums. The FCA should be now launching an urgent investigation into this matter demanding to see original "commercial sales" paperwork in order to see if Advanced has been as transparent as the rules dictate.
The Sunday Times today has splashed on the roll out of proton beam therapy centres in the UK. It states there are plans to build SIX centres in the UK...but....
There is no explanation at all given for today's resignation, with immediate effect, of Lord David Evans from the board of Advanced Oncotherapy (AVO). If it had been planned, as a result of illness or some other matter, it would have been announced with other board changes on October 10 and 27. Make no mistake: the reason that Evans has "resigned" is my scoop of 6 days ago regarding his share dealings - Congratulations you Blairite low life you have met The Sheriff of AIM.
Earlier today I pointed out how Lord David Evans, the senior NED at Advanced Oncotherapy (AVO) sold his entire holding of shares during a closed period and just ahead of a major placing. He appears only to have told the company this week, although the share sales took place between 19 August 2016 and 16 September 2016. This is a massive breach of AIM Rule 21. I have written to Marcus Stuttard, the head of the Oxymorons at AIM Regulation.
On 30 September 2016 Advanced Oncotherapy (AVO) announced not only its interim results but also a large placing at 100p. In the run-up to a placing and in the eight week closed period ahead of numbers surely no director could dump his entire holding? Surely not? Think again.
As indicated at the time of its bailout £10 million placing on September 30th, Advanced Oncotherapy (AVO) has now announced that it is to raise up to £4.8 million via an open offer at 100p. With the shares at 102p to sell, I'd rather sign up to spend two weeks alone on a desert island with crooked Hillary droning on about how being a rape enabler makes her a good feminist, than accept this offer.
Advanced Oncotherapy (AVO) announced its interim results on 22nd September 2015 and so you would expect that it will be publishing numbers for 2016 within the next week or so. The main question is whether it will be accompanied by a desperately needed placing of at last £35 million? But as we await that I wonder if the company would care to update us all on the true state of its UK sales pipeline. Telling the truth is not too much to ask is it?
On 25 March 2015 Advanced Oncotherapy (AVO) announced what it claimed was a major breakthrough in China, what it termed the "first major sale of a LIGHT system" in China. Well that was the headline. The customer was a firm called Sinophi. The shares zoomed on this $40 million order. Jolly good news. 37 days later the company raised £20 million in a placing at 8p. But did anyone care to look underneath the PR spin? No. Lets start with Sinophi Healthcare Limited.
Beaufort Securities is joint broker to grossly over-ramped Advanced Oncotherapy (AVO). That means a fat retainer and also a good slug of the commission earned for the regular placings this company needs to keep paying its bloated boardroom payroll and other costs. The commission on the May 2015 fundraise at 8p would have been £1 million. Coke & hookers all round! Except for the shareholders, that is, as the share price is now 5.25p and its going to fall further as the next placing is imminent. So how do you ramp a stock ahead of a placing?
One is not allowed to be beastly to companies that claim to be tackling cancer since we are all terrified of the big C. In fact cancer overwhelmingly affects old folks and so if ALL cancer was eliminated tomorrow,global life expectancy would increase by just 4 years. If we really want to change the world we'd be tacking the reason why younger folk die in poor countries rather than why older folk shuffle off this mortal coil a few years early in the West. But, heck, who cares about the darkies, let's look after folks closer to home. We are still all scared witless by the big C and if you have cancer or are close to someone who does you have my deepest sympathy. But it is that cloak of "we are doing good" that allows some folk to, if you will excuse the pun, make a killing. I today start a new series on Advanced Oncotherapy (AVO) by looking at boardroom pay.
Shares in Advanced Oncotherapy (AVO) are ahead smartly currently on the back of an announcement headlined “£24m financing secured for the provision of vendor financing by AVO for the Harley Street project”. Hmmm, let’s take a look…
Hello Share Slickers. I’ve already featured the bulletin board darling, Advanced Oncotherapy (AVO) this week. But as I’ve currently spent a large wodge of time researching this interesting share, it would be a waste not to bring you a bit more info and opinion on a share which has risen like a rocket and fallen like its stick. I think that fall has been overdone and punters are possibly waiting in the wings for a bit more news before they return to the stock.
Hello Share Crafters. In the past I’ve probably written too many pieces on a medical share which I like. During that period, I’ve seen the shares rise from 2p to 17p. Sadly, the share price has reversed back to 6.5p. And the worst of it is I bought a shedload more shares when they were around 10p. I refer, of course, to that darling of the bulletin boards Advanced Oncotherapy (AVO). I haven’t featured the company for some time now and it’s probably worth an update.
Featuring shares in 88 Energy (88E), Advanced Oncotherapy (AVO), Concha (CHA), Independent Oil & Gas (IOG), Independent Resources (IRG) and SolGold (SOLG) with share price targets for all six stocks.
I can’t exactly remember which New Year shares I tipped last year. But I recall that one of them Zytronic (ZYT) which does wonders with touch technology, was a cracking performer - I got a gold star for it in the performance table!
Issue 4 of the UK Investor Show Magazine is now out and can be accessed below. Jim Mellon, Rob Terry (prison update), the stockmarket crash (a buying opportunity?), Advanced Oncotherapy, 6 other share tips, accounting for Geeks from myself and Chris Bailey. There is something for everyone.
Hello Share Sliders.When I chose four shares to recommend to my student son Jack three weeks ago, he did his own research. Then he decided my suggestions were ok and piled in. He had £1,000 to play with, money he’d saved by chamber maid-ing at the holiday flats next door. So that was £250 in each company?
When I wrote about Advanced Oncotherapy (AVO) at the weekend, it was copied and pasted word for word, almost immediately into blogger’s corner at the LSE website.
On the principal that one should always put their money where one’s gob is, I try not to highlight shares, which I don’t already own. So let me begin this modest column by saying that, not only do I already own a heavy bundle of Advanced Oncatherapy (AVO) shares, but some of my friends and relatives have them, too.
Hello Fellow Share Bashers. The other day I told you how I’d picked five companies for my 21- year-old son Jack’s first share portfolio. But I was a bit miffed when he went off on a ten-day holiday to Denmark, without lodging his first £1000 with the broker. So far my fantastic five tips have gone unused.
Hello Share Pals, it's a thrilling time for my 21-year-old son, Jack. He has opened his very first share account with Traders Own. Being a student, he hasn't got much spare cash, but he has interred £1,000 into his golden fund. Now he needs five companies to dive into. I've got some suggestions for him below
Featuring AFC Energy (AFC), Advanced Oncotherapy (AVO), Xcite Energy (XEL), Xtract Resources (XTR)
I’m more than ever convinced, gang, that companies which are pushing at the medical frontier may boldly take our share portfolios to higher plains where they’ve never reached before.
If you want me to analyse a stock for you just drop me a line at [email protected] - Today I look at Advanced Oncotherapy (AVO), Alkane Energy (ALK), GW Pharmaceuticals (GWP).
Featuring 88 Energy (88E), Advanced Oncotherapy (AVO), Circle Oil (COP), Madagascar Oil (MOIL) and Patagonia Gold (PGD)
Hello Share Masters. I just want to return to Advanced Oncotherapy (AVO) as the boards seem to have gone quiet on this popular favourite among private punters.
Hello Sharemates. When a share bounces up fast, there is often a report on RNS saying the board knows no reason why the shares should have risen. Sometimes, it will add…’other than comments on bulletin boards’. This was the case with a little £3 million pound set-up, called Feedback (FDBK), which I highlighted this week. Before that, a message appeared from Advanced Oncotherapy (AVO) saying that the company did not know of reasons for a boost in share price after I wrote about it.
It seems as if some folks think that questioning the share price of Advanced Oncotherapy (AVO) is akin to attacking the fight against cancer. It is not. But in this podcast I just have a few questions
Hello Share Plinkers. A share which rises strongly over three days, nearly always drops back. We saw this with Lloyds Group (LLOY) over the last few weeks. It also happened to that darling of the bully boards, Advanced Oncotherapy (AVO) over the last six weeks.
Featuring Advanced Oncotherapy (AVO), Amphion Innovations (AMP), Central Rand Gold (CRND), Eurasia Mining (EUA), Valirx (VAL)
Advanced Oncotherapy (AVO) is one of the most talked-about shares on the net at the mo. And it’s not just the army of private bloggers who are desperately trying to talk up the share by making fortune teller predictions.
In the first of my Bulletin Board Heroes series I look at: Argos Resources (ARG), Advanced Oncotherapy (AVO), Boxhill Technologies (BOX), DQ Entertainment (DQE), Physiomics (PYC) and Richland Resources (RLD)
I have not done this before but I want to add a note about my recent Advanced Oncotherapy (AVO) share tip
Hello Share Munchkins. It’s not been so long ago that I was trumpeting Advanced Oncotherapy (AVO). But the fashionable biotech firm is beginning to get interesting again.
Bio-tech companies are a long way from my usual area of interest in oil, but given my view that we are likely to see lower oil prices in the near term, I’ve been looking elsewhere. An AIM company called Advanced Oncotherapy (AVO) has caught my eye recently – I know that fellow ShareProphets writer Malcolm Stacey is a big fan as well, and I was having a chat with him about it at the recent UK Investor Show.
Hello Share Trimmers. Investors in Advanced Oncotherapy (AVO) are in a peculiar situation. For though our shares are now trading at just a touch over 8p, they could be worth a lot more.
Hello Share Dribblers. I’ve had rather a dispiriting week. We all get them from time to time, even when the Footsie holds up very well, as it does now.
Not that long ago a five-year-old boy called Ashya King made the news in sad circumstances. He was taken away from an NHS hospital in Bristol and then grabbed by the police in Spain where his parents were arrested.
Hello Share Primpers. One of my three 2014 tips on this smashing website has made a one day leap of 75% as I write this.
Hello Share Movers. I have called your attention more than once to a firm called Advanced Oncotherapy (AVO). It is using the technology based on the Hadron Collider to develop a cancer treatment that is much cheaper and less bulky than older machines.
Hello Share Binders: There are lots of dilemmas that we have to address in Shareland. And in this heady environment, we realise that the wrong decision could cost us thousands of pounds.
Hello Share twitchers. I love trading penny shares. In and out, in and out, that’s the way to do it. Of course, the normally big spreads are a nuisance. But the rewards when a penny hits the red hot trail can be stunning.
Readers of this smasheroo website just get luckier and luckier – if you’ve been following my tips. Sorry, that sounds very immodest – but the only fault I have is over-modesty. Please forgive me, but I’m so excited about that anti-cancer outfit I recommended to you – Advanced Oncotherapy (AVO).
Hello Share Mates: Sadly, cancer is on the march in Britain and around the world. I'm sure we all know quite a few people who are affected. It's because we're getting older and the condition has a longer period to strike. But I also don't have to tell you that children and teenagers are at risk, too.
Search ShareProphets |
Recent Comments |